In one paragraphArticle in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Marianne AyoubDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.
Casilda HitierDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.
Léa DehganeDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.
Eliane MalletDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.
Mariana TannouryDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-1047-6614 Damien Roos-WeilDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-7767-755X Karim MaloumDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0001-8864-4801 Ingo RingshausenUniversity College London (UCL) Cancer Institute, London, UK.
Elise ChapiroDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-3427-7596 Florence Nguyen-KhacDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.
Delphine GarnierDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-5744-5612 Leticia K LernerDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France. leticia.koch-lerner@u-paris.fr.ORCID http://orcid.org/0000-0003-3476-5231 Santos A SusinDrug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Paris, France. santos.susin@sorbonne-universite.fr.ORCID http://orcid.org/0000-0002-3366-1628 Funding
Agence Nationale de la Recherche (French National Research Agency) ANR-19-CE14-0014Association Laurette Fugain (Laurette Fugain) 2024/11Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research) PDF20191209849Fondation de France WB-2021-35949Ligue Contre le Cancer RS19/75-59Ligue Contre le Cancer RS20/75-66Ligue Contre le Cancer RS25/75-76Ligue Contre le Cancer TADH27012
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
What OpenQuestion holds
Textmetadata
Read underepoch 390